SKIN: Squamous Skin Cancer REGN2810

A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Participants with Advanced Cutaneous Squamous Cell Carcinoma

Primary objective is to provide additional efficacy and safety data for cemiplimab monotherapy in patients with advanced CSCC (metastatic [nodal or distant] or locally advanced) treated with cemiplimab.

Principle Investigator: Prashanth Hari Dass.

This study is not yet open. Feel free to speak to the medical oncologist or oncology research nurse if you would like to receive more information.